In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an ¹²⁵I-labelled DNA-intercalator

References

• Allen BJ. (2008). Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials, 3, 185–191.
   PubMedGoogle Scholar
• Almgren M, Edwards K, Karlsson G. (2000). Cryo transmission electron microscopy of liposomes and related structures. Colloids and Surfaces, A: Physicochemical and Engineering Aspects, 174, 3–21.
   Web of Science ®Google Scholar
• Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F. (2003). Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett, 197, 231–235.
   PubMed Web of Science ®Google Scholar
• Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, Brandwein J, Minden M, Reilly RM. (2006). Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med, 47, 827–836.
   PubMed Web of Science ®Google Scholar
• Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (2007). (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med, 48, 1357–1368.
   PubMed Web of Science ®Google Scholar
• Costantini DL, Villani DF, Vallis KA, Reilly RM. (2010). Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. J Nucl Med, 51, 477–483.
   PubMed Web of Science ®Google Scholar
• Dubochet J, Adrian M, Chang JJ, Homo JC, Lepault J, McDowall AW, Schultz P. (1988). Cryo-electron microscopy of vitrified specimens. Q Rev Biophys, 21, 129–228.
   PubMed Web of Science ®Google Scholar
• Eldridge JS, Crowther P. (1964). Absolute determination of 125I. Nucleonics, 22
   Google Scholar
• El-Rayes BF, LoRusso PM. (2004). Targeting the epidermal growth factor receptor. Br J Cancer, 91, 418–424.
   PubMed Web of Science ®Google Scholar
• Elgqvist J, Andersson H, Bernhardt P, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L. (2006). Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab’)2. Int J Radiat Oncol Biol Phys, 66, 1228–1237.
   PubMed Web of Science ®Google Scholar
• Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L. (2010). Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging, 37, 114–123.
   PubMed Web of Science ®Google Scholar
• Ghirmai S, Mume E, Tolmachev V, Sjöberg S. (2005). Synthesis and radioiodination of some daunorubicin and doxorubicin derivatives. Carbohydr Res, 340, 15–24.
   PubMed Web of Science ®Google Scholar
• Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. (2005). Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med, 46, 2097–2103.
   PubMed Web of Science ®Google Scholar
• Ickenstein LM, Edwards K, Sjöberg S, Carlsson J, Gedda L. (2006). A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol, 33, 773–783.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res, 66, 6732–6740.
   PubMed Web of Science ®Google Scholar
• Lundqvist H, Stenerlöw B, Gedda L. (2008) “The Auger effect in molecular targeting therapy” in Stigbrand T, AGa CJ, ed. Targeted radionuclide tumor therapy, Springer Sciences + Business Media B.V.
   Google Scholar
• Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. (2005). Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res, 65, 11631–11638.
   PubMed Web of Science ®Google Scholar
• Mayer LD, Bally MB, Cullis PR. (1986). Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta, 857, 123–126.
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550–6565.
   PubMed Web of Science ®Google Scholar
• Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. (2004). Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med, 45, 129–137.
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. (1990). Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer, 45, 457–461.
   PubMed Web of Science ®Google Scholar
• Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. (2002). Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta, 1591, 109–118.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Press OW. (2010). Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer, 116, 1126–1133.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8, 1172–1181.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res, 66, 10073–10082.
   PubMed Web of Science ®Google Scholar
• Press MF, Cordon-Cardo C, Slamon DJ. (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5, 953–962.
   PubMed Web of Science ®Google Scholar
• Ranson M, Sliwkowski MX. (2002). Perspectives on anti-HER monoclonal antibodies. Oncology, 63 Suppl 1, 17–24.
   PubMed Web of Science ®Google Scholar
• Stigbrand T, Carlsson J, Adams G. (2008). Targeted Radioanuclide Tumor Therapy. Springer Science & Business Media B.V.
   Google Scholar
• Wheldon TE, O’Donoghue JA. (1990). The radiobiology of targeted radiotherapy. Int J Radiat Biol, 58, 1–21.
   PubMed Web of Science ®Google Scholar
• WHO. (2011). Cancer, fact sheet no 297. available at: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar